ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos ETM-26-2-12076 10.3892/etm.2023.12076 Articles Thrombectomy vs. medical management for large vessel occlusion strokes with minimal symptoms AnagnostopoulosIason-Stefanos 1 GeorgakopoulouVasiliki Epameinondas 2 TrakasIlias 2 PapalexisPetros 3 4 TrakasNikolaos 5 SpandidosDemetrios A. 6 FotakopoulosGeorge 7 Medical School, University of Ioannina, 45500 Ioannina, Greece Department of Infectious Diseases and COVID-19 Unit, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece Unit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece Department of Biomedical Sciences, University of West Attica, 12243 Athens, Greece Department of Biochemistry, Sismanogleio Hospital, 15126 Athens, Greece Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece Department of Neurosurgery, General University Hospital of Larisa, 41221 Larisa, Greece Correspondence to: Dr George Fotakopoulos, Department of Neurosurgery, General University Hospital of Larisa, Mezourlo 1, 41221 Larisa, Greece gfotakop@yahoo.gr guomanlisq@163.com 08 2023 23 06 2023 26 2 377 16 03 2023 09 06 2023 Copyright: © Anagnostopoulos et al. 2020 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Patients with acute ischemic stroke (AIS) presenting mild symptoms with a low National Institutes of Health Stroke Scale (NIHSS) score ≤8 and also found to have an intracranial large vessel occlusion (LVO) undergo endovascular thrombolysis (ET) or medical management alone. The current study aimed to evaluate the safety and effectiveness of medical management vs. ET therapy among patients with mild AIS symptoms (NIHSS score ≤8) accompanied by LVO. The present meta-analysis included articles involving mild AIS, LVO, thrombectomy/ET and medical management alone published in full-text form (from 1980 to 2022). Collected variables included: First author name, covered study period, publication year, the total number of patients and age, number of males, presence of diabetes mellitus, hypertension, atrial fibrillation, prior ischemic stroke, location, NIHSS of admission, modified Rankin scale, bleeding, morbidity and mortality. After the initial search and applying all exclusion and inclusion criteria, eight articles were left in the final article pool. The total number of patients who underwent ET was 569, compared with 1097 with medical management for LVO strokes with minimal symptoms. The findings of the present meta-analysis study point out that ET management may be associated with a high risk of bleeding and mortality in patients with LVO presenting with mild symptoms (NIHSS score ≤8).

 thrombectomy thrombolysis stroke bleeding medical treatment Funding: No funding was received. Introduction

Acute ischemic stroke (AIS) is one of the main reasons for death and disability, particularly in an aging society (1). In 61% of stroke patients, administering intravenous thrombolysis with different agents [medical management; urokinase (2.7%), streptokinase (36.8%) and alteplase, recombinant tissue plasminogen activator] within 3-4.5 h of symptom onset has a favorable outcome (2,3). Furthermore, previous studies suggested that medical management is safe and may benefit patients presenting mild AIS symptoms with a low National Institutes of Health Stroke Scale (NIHSS) score (NIHSS score ≤8) and who are also found to have an intracranial large vessel occlusion (LVO) (4-6).

Endovascular thrombolysis (ET), focusing on relieving vessel occlusion in stroke, has been developed as an alternative for medical management or as an adjunct in administration over the past few years (7,8). However, there is limited knowledge about the role of ET in patients with mild symptoms caused by LVO (9). Nonetheless, some studies also proposed that ET may be favorable in patients with severe symptoms (10).

Patients with mild AIS symptoms with an NIHSS score ≤8 also have an intracranial LVO presentation, requiring remarkably complex therapeutic management (11). Unfortunately, LVO in those patients is associated with poor outcomes; they present with mild deficits (12) and because of weak collateral conditions, they can worsen rapidly or progressively (13). Thus, the need for any acute management is often debated since these patients ‘only’ have mild defects and any therapy has related risks (11).

Given these conflicting observational reports and the lack of randomized data, the present study aimed to evaluate the safety and effectiveness of medical management vs. ET therapy among patients with mild AIS symptoms (NIHSS score ≤8) accompanied by LVO.

 Materials and methods <sec> <title>Search strategy

The study searched the comparative articles involving mild AIS and LVO, thrombectomy, and medical management through electronic databases, including the Cochrane Library, Medline (1980-2022.12), PubMed (1980-2022.12), and EMBASE (1980-2022.12). Preferred reporting items for systematic reviews and meta-analyses were applied for establishing protocol and manuscript design (14). The keywords ‘mild acute ischemic stroke’, ‘large vessel occlusion’ and ‘thrombectomy/endovascular thrombolysis and medical management’, which are present in the MeSH list, were used for database search.

 Selection of studies

Two of the reviewers (GF and VEG) independently extracted data from the included articles, following the guidelines of the epidemiology of meta-analysis. The following basic information was captured: Main authors; year of publication; total case number in the thrombectomy and medical management groups; study type; outcome indicator; diabetes; hypertension; atrial fibrillation; location; prior ischemic stroke; NIHSS of admission. The extracted data were input into a table designed and standardized according to the Cochrane Handbook. Fig. 1 depicts the flow of the study selection process. In case of disagreement on the information to be retained, another author with authority (this authority was decided upon by all authors prior to commencing the research) had the final say.

Inclusion and exclusion criteria. If an article satisfied the following PICOS criteria, it was considered for inclusion in the present meta-analysis: i) Population limited to patients with mild acute ischemic stroke (NIHSS score ≤8) and LVO on CT angiography [middle cerebral artery M1/M2, intracranial carotid artery (ICA) or vertebrobasilar occlusion]; ii) intervention limited to ET or medical management; iii) studies comparing the outcomes between ET and medical management; iv) one of the primary outcomes, such as morbidity and mortality, was involved. To avoid publication bias, the final aim was to collect a homogenous pool of manuscripts, including articles that compare only two intervention modalities, i.e. ET and medical management. Table I contains detailed data on these articles.

All prospective and retrospective studies that evaluated at least one of the two modalities were included, whereas editorials, reviews, case reports and articles focusing on the pediatric population, unrelated outcomes, co-morbidities, experimental techniques, or one of the two modalities from that article pool, were excluded. In addition, in the case of studies with mixed or unclear results, the corresponding information was removed or was placed into groups accordingly, although without affecting the ratio.

 Outcomes' definition

The primary outcomes involved in the present study included mortality and post-intervention morbidity (Karnofsky Performance Score-KPS <80). In addition, to find out the association between ET and medical management, the present collected outcome measurements (secondary outcomes) such as the rates of modified Rankin scale (mRS) scores 0-2 (indicating a good outcome) at discharge and long-term follow-up (3 months for the interventional cohort and bleeding after the intervention). The outcomes reported in the included articles were assessed at least three months after the ET or medical management for large vessel occlusion strokes with minimal symptoms. Additionally, a quality assessment tool was used to decrease the risk of bias in our poor articles (Newcastle-Ottawa Scale; Table II) (15).

 Evaluation of the risk of bias

The Cochrane Collaboration tool was used by two reviewers (GF and VEG) to assess the risk of bias in each study (16). The evaluation included random sequence generation, allocation concealment, blinding of participants and assessors, blinding of outcome assessment, incomplete outcome data, selective reporting and other biases (such us criteria of ‘unclear risk’ of bias; this was in the case of insufficient available information to assess whether an important risk of bias exists or insufficient evidence that an identified problem will introduce bias. The assessment results were classified into low, high and unclear risk levels. The third reviewer arbitrated any disagreements.

 Data synthesis and assessment of heterogeneity

All analyses were carried out using Review Manager Software v5.4 (RevMan; https://training.cochrane.org/online-learning/core-software/revman). Heterogeneity across trials was identified using I2 statistics; considering I2 >50% as high heterogeneity, a meta-analysis was conducted using a random-effect model according to the Cochrane Handbook for Systematic Reviews of Interventions (v5.1.0) (17). Otherwise, a meta-analysis using the fixed-effect model was performed. The continuous outcomes were expressed as a weighted mean difference with 95% confidence intervals (CIs). For discontinuous variables, odds ratios (OR) with 95% CIs were applied for the assessment. To test the sensitivity, the ‘leave out one’ model was used by removing one study at a time. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Articles meeting criteria

A total of eight articles met the eligibility criteria (18-25). The total number of patients was 569 who underwent ET and 1097 with medical management for LVO strokes with minimal symptoms. The study sample was based on eight studies (Table II). Among these, five were retrospective and three were prospective observational studies.

 Epidemiological and clinical features

The mean age of the patients was 70.46 years (range, 53-72 years; 64.06 and 76.93 years for the ET and the medical management sample, respectively). The male-to-female ratio was 1:1.7. Diabetes was diagnosed in 325/1666 (19.5%) of patients (123/569 and 202/1097 in the ET and the medical management group, respectively), hypertension in 1186/1666 (71.1%) of patients (405/569 and 781/1097 in the ET and medical management groups, respectively), and atrial fibrillation in 378/1666 (22.6%) of patients (141/569 and 237/1097 in the ET and medical management groups, respectively) (Table I).

 Diabetes mellitus

Information regarding diabetes mellitus was available in eight articles (18-25) and demonstrated no statistical result (OR 1.07, CI 95% 0.58-1.40; P=0.61) with no heterogeneity (P=0.56 and I2=0%) (Fig. S1). Diabetes mellitus was found in 325 of the 1666 (19.5%) patients in the total group. In the ET group, diabetes mellitus was diagnosed in 123 of 569 (21.6%) patients, compared with 202 of 1097 (18.4%) in the medical management group. Looking at the funnel plot of the same parameter, no publication bias was found.

 Hypertension

As regards hypertension, information was available in eight articles (18-25) and demonstrated no statistical result (OR 1.87, CI 95% 0.68-1.10; P=0.23) with no heterogeneity (P=0.83 and I2=0%) (Fig. S2). Hypertension was found in 1186 of 1666 (71.1%) patients in the total group. In the ET group, hypertension was diagnosed in 405 of 569 (71.1%) patients, compared with 781 of 1097 (71.1%) in the medical management group. Looking at the funnel plot of the same parameter, no publication bias was found.

 Atrial fibrillation

Atrial fibrillation data were available in eight articles (18-25). Atrial fibrillation was reported for 378 of the 1666 (22.6%) patients in the total group and 141 of the 569 (28.2%) patients in the ET group. The statistical analysis demonstrated no statistically significant difference (OR 1.27, CI 95% 0.85-1.91; P=0.24), but indicated heterogeneity (P=0.07 and I2=48%) (Fig. 2A). By testing sensitivity (Table III), after removing the article by ‘Kastrup et al, 2018’ (23), a statistically significant difference result was found (OR 1.61, CI 95% 1.18-2.21; P<0.05), with no heterogeneity (P=0.52 and I2=0%) (Fig. 2B). The total sample size for this combination was 247 (18.1%) out of 1361, of which 84 (19.8%) out of 424 were from the ET group and 163 (17.3%) out of 937 were from the medical management group. Looking at the funnel plot of the same parameter, it was found that the study results without the Karstup et al, 2018 article (23) displayed an improved dispersion with no publication bias (Fig. 2C and D).

 Prior ischemic stroke

As regards the prior ischemic stroke, the total number of patients was 159 (9.5%) out of 1666 patients, of which 52 out of 569 (9.1%) were from the ET group and 107 out of 1097 (9.7%) were from the medical management group. The statistical analysis demonstrated no significant difference (OR 0.97, CI 95% 0.56-1.70; P=0.93) but indicated heterogeneity (P=0.21 and I2=32%) (Fig. S3A). By testing the sensitivity (Table III), low heterogeneity (P=0.32 or and I2=14%) was achieved only after removing the articles by ‘Urra et al, 2014’ (18) or ‘Wang et al, 2020’ (24), as the combination with the removed article by ‘Urra et al, 2014’ (18) was of higher quality because the total sample was 152 compared with 146 in the combination without the article by ‘Wang et al, 2020’ (24) (Table III). However, it was found again no statistically significant difference (OR 0.90, CI 95% 0.60-1.36; P=0.63) (Fig. S3B). Looking at the funnel plot of the same parameter, it was found that the study results without the ‘Urra et al, 2014’ (18) article displayed an improved dispersion with low publication bias (Fig. S3C and D).

 MRS 0-2 after 3 months

As regards the mRS 0-2 after 3 months, the total number of patients was 1,107 (66.4%) out of 1,666 patients in the total group, of which 372 (65.3%) out of 569 were from the ET group and 735 (67.0%) out of 1097 patients were from the medical management group. The statistical analysis demonstrated no significant difference (OR 1.23, CI 95% 0.79-1.93; P=0.37) but indicated some heterogeneity (P=0.03 and I2=55%) (Fig. 3A). By testing the sensitivity (Table IV), low heterogeneity (P=0.16 and I2=35%) was achieved only after removing the article by ‘Nagel et al, 2018’ (21) but it was found again no statistically significant difference (OR 1.01, CI 95% 0.68-1.50; P=0.96) (Fig. 3B). Looking at the funnel plot of the same parameter, it was found that the study results without the ‘Nagel S et al, 2018’ (21) article displayed an improved dispersion with low publication bias (Fig. 3C and D).

 Bleeding

Information regarding bleeding was available in seven out of eight articles (18-22,24,25) and demonstrated a statistical result (OR 3.13, CI 95% 1.65-5.95; P<0.05) with no heterogeneity (P=0.33 and I2=14%) (Fig. 4). Bleeding was found in 60 out of 1666 (3.6%) patients in the total group. In the ET group, bleeding was diagnosed in 39 out of 129 (30.2%) patients, compared with 21 out of 1097 (1.9%) in the medical management group. Looking at the funnel plot of the same parameter, it was found a very low publication bias.

 Morbidity

Morbidity data were available in six of the eight articles (18,20-22,24,25): A total of 199 (20.3%) from 976 included patients; and poor KPS in 89 (21.3%) of 416 patients from the ET group. The statistical analysis demonstrated no significant difference (OR 1.02, CI 95% 0.64-1.63; P=0.94) and indicated heterogeneity (P=0.14 and I2=39%) (Fig. 5A). By testing the sensitivity (Table IV), no heterogeneity (P=0.57 and I2=0%) was achieved only after removing the article by ‘Wang et al, 2020’ (24) but again without a statistically significant difference (OR 0.87, CI 95% 0.61-1.24; P=0.45) (Fig. 5B). Looking at the funnel plot of the same parameter, it was found that the study results without the ‘Wang et al, 2020’ (24) article displayed an improved dispersion with no publication bias (Fig. 5C and D).

 Mortality

Mortality data were available in six of the eight articles (18,19,21,22,24,25): A total of 81/1,243 (6.5%) patients, including 30 out of 394 (7.6%) from the ET group and 51 (6.0%) out of 849 from the medical management group. The statistical analysis demonstrated no statistically significant difference (OR 1.37, CI 95 % 0,55-3.41; P=0.50) but indicated heterogeneity (P=0.10 and I2=45 %) (Fig. 6A). By testing the sensitivity (Table IV), after removing the article by ‘Nagel S et al, 2018’ (21), it was found a statistically significant difference (OR 1.94, CI 95% 1.02-3.69; P<0.05) with no heterogeneity (P=0.40 and I2=2%) (Fig. 6B). Looking at the funnel plot of the same parameter, it was found that the study results without the ‘Nagel S et al, 2018’ (21) article displayed an improved dispersion with very little publication bias (Fig. 6C and D).

 Discussion

The present study suggested that medical management for LVO strokes with minimal symptoms was associated with fewer complications compared with ET intervention. More precisely, atrial fibrillation was the only statistically significant parameter related to bleeding and mortality in patients with LVO strokes with minimal symptoms. Interestingly, the rates of the mRS score of 0-2 (indicating a good outcome) at discharge and the morbidity (KPS <80) showed no association with medical management or ET therapy in those patients.

The findings of the present meta-analysis pointed out that ET therapy may be associated with a high risk of bleeding and mortality in patients with LVO presenting with mild symptoms (NIHSS score ≤8).

The absence of benefits from ET therapy is consistent with the findings of several previous studies (26-29). However, a multicenter observational study reported that ET therapy was effective in recanalizing the occluded vessel but increased the risk of serious bleeding significantly without improving the functional outcome, suggesting that it was not justified routinely in minor strokes (18). The current study showed that ET therapy is related to a high risk of bleeding and mortality in patients with LVO presenting mild symptoms (NIHSS score ≤8). This may be attributed to several reasons, such as the acceptable collateral condition that developed in patients with LVO and mild symptoms, which predisposes to bleeding and reduces the advantages of ET.

In addition, the recent meta-analysis showed that ET therapy, compared with medical management alone, is associated with higher rates of bleeding and mortality outcomes in patients with atrial fibrillation. A possible explanation is the higher proportion of atrial fibrillation in the ET group, an extensively reported risk factor for intracerebral haemorrhage (30,31).

In agreement with previous cohorts of patients presenting with mild symptoms, the treatment modality had a high percentage of good early clinical outcomes and an excellent early clinical outcome (23); however, even after excluding patients with contraindications for an ET, the clinical outcome was not significantly different between ET and medical management in patients with an admission NIHSS ≤8. The aforementioned results are similar to the ones shown in the present study, with mRS 0-2 and morbidity having no association with medical management or ET therapy in those patients.

Prior studies reported on outcomes achieved using ET therapy in milder stroke patients but were limited because of a single-center study design (20), a small number of patients (18-20) or the lack of a similar medical management group (32). These uncertain results highlight the need for higher-quality data for this population.

There are several limitations in the present study. First, most of the eligible reports that were included were retrospective. These retrospective studies are affected by low accuracy and data loss. Additionally, the study design differed significantly among the included studies, e.g. the duration of follow-up (e.g., 30-90 days).

In conclusion, the routine use of ET was not significantly favorable for the early clinical or radiological outcome in patients with mild strokes and LVO compared with medical management alone. However, the present results suggested that ET could be beneficial only in patients with NIHSS ≥8. It is also undisputable that a randomized trial is needed to determine the difference in outcome between these two treatment modalities in these patients.

 Supplementary Material Diabetes mellitus ORs. (A) Forest plot of diabetes mellitus ORs demonstrated no statistically significant difference between the groups (total OR 1.07, CI 95% 0.58-1.40; p 0.61). (B) Funnel plot of the diabetes mellitus ORs demonstrated no heterogeneity in the groups (P=0.56, and I<sup>2</sup>=0%). ET, endovascular thrombolysis; medical, medical management; OR, odds ratio. Hypertension ORs. (A) Forest plot hypertension ORs demonstrated no statistically significant results (total OR 1.87, CI 95% 0.68-1.10; P=0.23). (B) Funnel plot of the hypertension ORs demonstrated no heterogeneity in the groups (P=0.83 and I<sup>2</sup>=0%). ET, endovascular thrombolysis; medical, medical management; OR, odds ratio. Prior ischemic stroke ORs. (A) Forest plot of prior ischemic stroke ORs demonstrated no statistically significant difference groups (total OR 0.97, CI 95% 0.56-1.70; P=0.93). (B) Forest plot of prior ischemic stroke ORs without ‘Urra <italic>et al</italic> 2014’ (18) article demonstrated no statistically significant difference between the groups (total OR 0.90, CI 95% 0.60-1.36; P=0.63). (C) Funnel plot of the prior ischemic stroke ORs between groups, with ‘Urra <italic>et al</italic>, 2014’(18) article and with heterogeneity (P=0.21 and I<sup>2</sup>=32%). (D) Funnel plot of the prior ischemic stroke ORs between groups, without ‘Urra <italic>et al</italic>, 2014’(18) article, and very low heterogeneity (P=0.32 and I<sup>2</sup>=14%). Medical, medical management; OR, odds ratio. Acknowledgements

Not applicable.

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

GF and VEG conceptualized the study. VEG, IT, GF, PP, ISA, DAS and NT analyzed the data and wrote and prepared the draft of the manuscript. VEG and GF provided critical revisions. All authors contributed to the manuscript revision. All authors read and approved the final manuscript. GF and VEG confirm the authenticity of all the raw data.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article.

 References FeiginVLRothGANaghaviMParmarPKrishnamurthiRChughSMensahGANorrvingBShiueINgMGlobal burden of stroke and risk factors in 188 countries, during 1990-2013: A systematic analysis for the global burden of disease study 2013Lancet Neurol1591392420162729152110.1016/S1474-4422(16)30073-4 HackeWKasteMBluhmkiEBrozmanMDávalosAGuidettiDLarrueVLeesKRMedeghriZMachnigTThrombolysis with alteplase 3 to 4.5 hours after acute ischemic strokeN Engl J Med3591317132920081881539610.1056/NEJMoa0804656 IST-3 collaborative groupEffect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes [the third International Stroke Trial (IST-3)]: 18-month follow-up of a randomised controlled trialLancet Neurol1276877620132379182210.1016/S1474-4422(13)70130-3 StrbianDPiironenKMeretojaASairanenTPutaalaJTiainenMArttoVRantanenKHäppöläOKasteMHelsinki stroke thrombolysis registry group: Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptomsInt J Stroke829329920132256887710.1111/j.1747-4949.2012.00808.x KöhrmannMNoweTHuttnerHBEngelhornTStruffertTKollmarRSaakeMDoerflerASchwabSSchellingerPDSafety and outcome after thrombolysis in stroke patients with mild symptomsCerebrovasc Dis2716016620091909223710.1159/000185607 BaumannCRBaumgartnerRWGandjourJvon BüdingenHCSiegelAMGeorgiadisDGood outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptomsStroke371332133320061655688110.1161/01.STR.0000217272.38455.a2 MeyersPMSchumacherHCConnollyES JrHeyerEJGrayWAHigashidaRTCurrent status of endovascular stroke treatmentCirculation1232591260120112164650610.1161/CIRCULATIONAHA.110.971564 PierotLSoizeSBenaissaAWakhlooAKTechniques for endovascular treatment of acute ischemic stroke: From intra-arterial fibrinolytics to stent-retrieversStroke4690991420152565718510.1161/STROKEAHA.114.007935 SelimMHMolinaCAManagement of acute stroke patients with rapidly resolving deficits and persistent vascular occlusion: A real clinical equipoiseStroke413007300820102103069510.1161/STROKEAHA.110.597427 BroderickJPPaleschYYDemchukAMYeattsSDKhatriPHillMDJauchECJovinTGYanBSilverFLEndovascular therapy after intravenous t-PA versus t-PA alone for strokeN Engl J Med36889390320132339092310.1056/NEJMoa1214300 CerejoRCheng-ChingEHuiFHussainMSUchinoKBullenJTothGTreatment of patients with mild acute ischemic stroke and associated large vessel occlusionJ Clin Neurosci30606420162705091610.1016/j.jocn.2015.12.029 HeldnerMRZublerCMattleHPSchrothGWeckAMonoMLGrallaJJungSEl-KoussyMLüdiRNational institutes of health stroke scale score and vessel occlusion in 2152 patients with acute ischemic strokeStroke441153115720132347126610.1161/STROKEAHA.111.000604 MokinMMasudMWDumontTMAhmadGKass-HoutTSnyderKVHopkinsLNSiddiquiAHLevyEIOutcomes in patients with acute ischemic stroke from proximal intracranial vessel occlusion and NIHSS score below 8J Neurointerv Surg641341720142384344310.1136/neurintsurg-2013-010720 FosterRLReporting guidelines: Consort, prisma, and squireJ Spec Pediatr Nurs171220122218826610.1111/j.1744-6155.2011.00319.x WellsGASheaBO'ConnellDPetersonJWelchVLososMTugwellPThe newcastle-ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, Ottawa, ON, 2014. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. HigginsJPAltmanDGGøtzschePCJüniPMoherDOxmanADSavovicJSchulzKFWeeksLSterneJAThe cochrane collaboration's tool for assessing risk of bias in randomised trialsBMJ343d592820112200821710.1136/bmj.d5928 Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Updated March 2011. UrraXRománLSGilFMillánMCánovasDRoquerJCardonaPRibóMMartí-FàbregasJAbilleiraSMedical and endovascular treatment of patients with large vessel occlusion presenting with mild symptoms: An observational multicenter studyCerebrovasc Dis3841842420142547257610.1159/000369121 HaussenDCBouslamaMGrossbergJAAndersonABelagageSFrankelMBianchiNRebelloLCNogueiraRGToo good to intervene? Thrombectomy for large vessel occlusion strokes with minimal symptoms: An intention-to-treat analysisJ Neurointerv Surg991792120172758986110.1136/neurintsurg-2016-012633 HaussenDCLimaFOBouslamaMGrossbergJASilvaGSLevMHFurieKKoroshetzWFrankelMRNogueiraRGThrombectomy versus medical management for large vessel occlusion strokes with minimal symptoms: An analysis from STOPStroke and GESTOR cohortsJ Neurointerv Surg1032532920182876882010.1136/neurintsurg-2017-013243 NagelSBouslamaMKrauseLUKüpperCMesserMPetersenMLowensSHerzbergMRinglebPAMöhlenbruchMAMechanical thrombectomy in patients with milder strokes and large vessel occlusionsStroke492391239720183035508610.1161/STROKEAHA.118.021106 SarrajAHassanASavitzSIGrottaJCCaiCParshaKNFarrellCMImamBSittonCWReddySTEndovascular thrombectomy for mild strokes: How low should we go?Stroke492398240520183035509410.1161/STROKEAHA.118.022114 KastrupABrunnerFHildebrandtHRothCWinterhalterMGiessingCPapanagiotouPEndovascular therapy versus thrombolysis in patients with mild strokes and large vessel occlusions within the anterior circulationInterv Neurol743143820183041052110.1159/000489708 WangGFZhaoXLiuSPXiaoYLLuZNEfficacy and safety of mechanical thrombectomy for acute mild ischemic stroke with large vessel occlusionMed Sci Monit26e92611020203262864510.12659/MSM.926110 XueRZhongWZhouYHeYYanSChenZWangJGongXLouMEndovascular treatment for minor acute ischemic strokes with large vessel occlusionJ Am Heart Assoc11e02732620223653362210.1161/JAHA.122.027326 VolnyOZernaCTomekABarMRocekMPadrRCihlarFNevsimalovaMJurakLHavlicekRThrombectomy vs medical management in low NIHSS acute anterior circulation strokeNeurology95e3364e337220203298910010.1212/WNL.0000000000010955 GoyalNTsivgoulisGMalhotraKIshfaqMFPandhiAFrohlerMTSpiottaAMAnadaniMPsychogiosMMausVMedical management vs mechanical thrombectomy for mild strokes: An international multicenter study and systematic review and meta-analysisJAMA Neurol77162420203154535310.1001/jamaneurol.2019.3112 MannoCDisantoGBiancoGNannoniSHeldnerMJungSArnoldMKaesmacherJMüllerMThilemannSOutcome of endovascular therapy in stroke with large vessel occlusion and mild symptomsNeurology93e1618e162620193159127610.1212/WNL.0000000000008362 WuXKhunteMPayabvashSZhuCBrackettAMatoukCGandhiDSanelliPMalhotraAOutcomes after thrombectomy for minor stroke: A meta-analysisWorld Neurosurg149e1140e115420213335988110.1016/j.wneu.2020.12.047 TianBTianXShiZPengWZhangXYangPLiZZhangXLouMYinCClinical and imaging indicators of hemorrhagic transformation in acute ischemic stroke after endovascular thrombectomyStroke531674168120223487234110.1161/STROKEAHA.121.035425 Van KranendonkKRTreurnietKMBoersAMMBerkhemerOAvan den BergLAChalosVLingsmaHFvan ZwamWHvan der LugtAvan OostenbruggeRJClinical and imaging markers associated with hemorrhagic transformation in patients with acute ischemic strokeStroke502037204320193375549710.1161/STROKEAHA.118.024255 DargazanliCConsoliAGoryBBlancRLabreucheJPredaCBourdainFDecroixJPRedjemHCiccioGIs reperfusion useful in ischaemic stroke patients presenting with a low national institutes of health stroke scale and a proximal large vessel occlusion of the anterior circulation?Cerebrovasc Dis4330531220172838463210.1159/000468995

Flow chart.

Atrial fibrillation ORs. (A) Forest plot of atrial fibrillation ORs demonstrated no statistically significant difference between the groups (total OR 1.27, CI 95% 0.85-1.91; P=0.24). (B) Forest plot of atrial fibrillation ORs obtained by excluding the ‘Kastrup et al, 2018’ (23) article demonstrated a statistically significant difference between the groups, (total OR 1.61, CI 95% 1.18-2.21; P<0.05). (C) Funnel plot of the atrial fibrillation between groups, with ‘Kastrup A et al 2018’ (23) article and with heterogeneity (P=0.07 and I2=48 %). (D) Funnel plot of the atrial fibrillation between groups, without ‘Kastrup A et al, 2018’ (23) article and without heterogeneity (P=0.52 and I2=0%). ET, endovascular thrombolysis; medical, medical management; OR, odds ratio.

MRS 0-2 ORs after 3 months. (A) Forest plot of mRS 0-2 ORs after 3 months demonstrated no statistically significant difference between the groups (total OR 1.23, CI 95% 0.79-1.93; P=0.37). (B) Forest plot of mRS 0-2 ORs after 3 months obtained by excluding the ‘Nagel et al, 2018’ (21) article demonstrated again no statistically significant difference between groups (total OR 1.01, CI 95% 0.68-1.50; P=0.96). (C) Funnel plot of the mRS 0-2 ORs after 3 months between the groups, including the ‘Nagel et al, 2018’ (21) article and with heterogeneity (P=0.03 and I2=55%). (D) Funnel plot of the mRS 0-2 OR after 3 months between groups, without ‘Nagel et al, 2018’ (21) article and with low heterogeneity (P=0.16 and I2=35%). MRS, modified Rankin scale; OR, odds ratio.

Bleeding ORs. (A) Forest plot of the bleeding ORs demonstrated a statistically significant difference between groups (total OR 3.13, CI 95% 1.65-5.95; P<0.05). (B) Funnel plot of the bleeding ORs demonstrated very low heterogeneity (P=0.33, and I2=14%). Medical, medical management; OR, odds ratio.

Morbidity ORs. (A) Forest plot of morbidity ORs demonstrated no statistically significant difference between groups (total OR 1.02, CI 95% 0.64-1.63; P=0.94). (B) Forest plot of morbidity ORs obtained by excluding the ‘Wang et al, 2020’ (24) article demonstrated again no statistically significant difference between the groups (total OR 0.87, CI 95% 0.61-1.24; P=0.45). (C) Funnel plot of the morbidity ORs between groups, with the ‘Wang et al 2020’ (24) article and heterogeneity (P=0.14 and I2=39%). (D) Funnel plot of the morbidity ORs between groups, without the ‘Wang et al 2020’ (24) article and heterogeneity (P=0.57 and I2=0%). OR, odds ratio.

Mortality ORs. (A) Forest plot of mortality ORs demonstrated no statistically significant difference between groups (total OR 1.37, CI 95 % 0.55-3.41; P=0.50). (B) Forest plot of mortality ORs without the ‘Nagel et al, 2018’ (21) article demonstrated a statistically significant difference between the groups (total OR 1.94, CI 95% 1.02-3.69; P<0.05). (C) Funnel plot of the mortality ORs between the groups, with the ‘Nagel et al, 2018’ (21) article and with heterogeneity (P=0.10 and I2=45%). (D) Funnel plot of the mortality ORs between groups without the ‘Nagel et al, 2018’ (21) article and without heterogeneity (P=0.40 and I2=2%). ET, endovascular thrombolysis; medical, medical management; OR, odds ratio.

Design and baseline characteristics of the included trials.

  Sample size, n Mean age (years) No. of males Diabetes Hypertension Atrial fibrillation  
First author/s, year Throm Medic Throm Medic Throm Medic Throm Medic Throm Medic Throm Medic (Refs.)
Urra et al, 2014 34 44 64 71 24 26 6 6 21 29 9 14 (18)
Haussen et al, 2016 10 22 60 68.2 5 15 2 4 6 13 3 8 (19)
Haussen et al, 2017 30 88 63.5 73 15 41 9 10 21 63 10 16 (20)
Nagel et al, 2018 80 220 65.3 69.5 44 117 13 36 56 159 35 62 (21)
Sarraj et al, 2018 124 90 65.8 65.4 72 51 36 27 87 72 NR NR (22)
Kastrup et al, 2018 145 160 71 72 65 67 32 35 122 129 57 74 (23)
Wang et al, 2020 23 24 53.9 64.4 17 17 4 6 17 17 2 2 (24)
Xue et al, 2022 123 449 69 68 82 307 21 78 75 299 25 61 (25)
  Location  
  Prior to ischemic stroke ICA M1 M2 Vertebrobasilar NIHSS of admission  
First author/s, year Throm Medic Throm Medic Throm Medic Throm Medic Throm Medic Throm Medic (Refs.)
Urra et al, 2014 5 2 0 1 13 13 7 16 12 12 4 3 (18)
Haussen et al, 2016 2 7 0 3 6 10 1 5 2 3 4 2 (19)
Haussen et al, 2017 NR NR 2 17 11 17 9 17 7 11 4 3 (20)
Nagel et al, 2018 NR NR 10 26 33 48 23 108 6 15 4 3 (21)
Sarraj et al, 2018 22 12 21 12 68 21 33 44 0 0 4 3 (22)
Kastrup et al, 2018 NR NR 32 19 62 76 51 65 0 0 8 7 (23)
Wang et al, 2020 4 9 6 8 10 5 2 2 5 9 3 3 (24)
Xue et al, 2022 19 77 34 110 59 213 20 83 12 12 3 3 (25)
  mRS 0-2 after 3 months Bleeding Morbidity Mortality      
First author/s, year     Throm Medic Throm Medic Throm Medic Throm Medic     (Refs.)
Urra et al, 2014     1 1 4 0 14 14 4 2     (18)
Haussen et al, 2016     10 17 0 0 1 5 0 3     (19)
Haussen et al, 2017     29 64 2 0 NR NR NR NR     (20)
Nagel et al, 2018     68 154 4 3 8 36 3 20     (21)
Sarraj et al, 2018     78 61 17 9 35 28 11 1     (22)
Kastrup et al, 2018     86 89 NR NR 19 22 NR NR     (23)
Wang et al, 2020     16 18 2 0 12 5 1 1     (24)
Xue et al, 2022     84 331 10 9 NR NR 11 24     (25)

M, middle cerebral artery; Throm, thrombectomy; medic, medical management; mRS, modified Rankin scale; NR, not reported.

NOS quality assessment of final article pool.

  NOS  
First author/s, year Study design Selection Comparability Exposure Total scores (Refs.)
Urra et al, 2014 Prosp 3 3 3 9 (18)
Haussen et al, 2016 Prosp 3 3 3 9 (19)
Haussen et al, 2017 Retro 3 2 2 7 (20)
Nagel et al, 2018 Prosp 3 3 3 9 (21)
Sarraj et al, 2018 Retro 3 2 2 7 (22)
Kastrup et al, 2018 Retro 3 2 2 7 (23)
Wang et al, 2020 Retro 3 2 2 7 (24)
Xue et al, 2022 Retro 3 2 2 7 (25)

Retro, retrospective; Prosp, prospective; NOS, Newcastle-Ottawa Scale.

Meta-analysis of clinical parameters.

  Groups Overall effect Heterogeneity  
Parameters Excluded trials Trials, n Throm Medic Effect estimate CI 95% P-value I2 (%) P-value (Refs.)
Atrial fibrillation None 8 141 237 1.27 0.85-1.91 0.24 48 0.07 (18-25)
  Urra et al, 2014 7 132 223 1.36 0.87-2.12 0.18 52 0.06 (18)
  Haussen et al, 2016 7 138 229 1.31 0.85-2.03 0.22 55 0.05 (19)
  Haussen et al, 2017 7 131 221 1.18 0.76-1.82 0.46 49 0.08 (20)
  Nagel et al, 2018 7 106 175 1.13 0.73-1.73 0.58 36 0.17 (21)
  Sarraj et al, 2018 7 141 237 1.27 0.85-1.91 0.24 48 0.07 (22)
  Kastrup et al, 2018 7 84 163 1.61 1.18-2.21 <0.05 0 0.52 (23)
  Wang et al, 2020 7 139 235 1.28 0.83-1.98 0.26 56 0.04 (24)
  Xue et al, 2022 7 116 176 1.19 0.72-1.97 0.50 51 0.07 (25)
Prior to ischemic stroke None 8 52 107 0.97 0.56-1.70 0.93 32 0.21 (18-25)
  Urra et al, 2014 7 47 105 0.90 0.60-1.36 0.63 14 0.32 (18)
  Haussen et al, 2016 7 50 100 1.03 0.55-1.96 0.92 45 0.14 (19)
  Haussen et al, 2017 7 52 107 0.97 0.56-1.70 0.93 32 0.21 (20)
  Nagel et al, 2018 7 52 107 0.97 0.56-1.70 0.93 32 0.21 (21)
  Sarraj et al, 2018 7 30 95 0.84 0.39-1.78 0.65 36 0.20 (22)
  Kastrup et al, 2018 7 52 107 0.97 0.56-1.70 0.93 32 0.21 (23)
  Wang et al, 2020 7 48 98 1.10 0.68-1.80 0.69 14 0.32 (24)
  Xue et al, 2022 7 33 30 1.01 0.41-2.49 0.99 46 0.13 (25)
Diabetes mellitus None 8 123 202 1.07 0.58-1.40 0.61 0 0.56 (18-25)
Hypertension None 8 405 781 0.87 0.68-1.10 0.23 0 0.83 (18-25)

Throm, thrombectomy; medic, medical management; mRS, modified Rankin Scale.

Meta-analysis of clinical outcomes.

  Groups Overall effect Heterogeneity  
Outcomes Excluded trials Trials, n Throm Medic Effect estimate CI 95% P-value I2 (%) P-value (Refs.)
mRS 0-2 None 8 372 735 1.23 0.79-1.93 0.37 55 0.03 (18-25)
  Urra et al, 2014 7 371 734 1.24 0.77-1.99 0.37 61 0.02 (18)
  Haussen et al, 2016 7 362 718 1.18 0.76-1.85 0.46 58 0.03 (19)
  Haussen et al, 2017 7 343 671 1.10 0.75-1.61 0.63 43 0.10 (20)
  Nagel et al, 2018 7 304 581 1.01 0.68-1.50 0.96 35 0.16 (21)
  Sarraj et al, 2018 7 294 674 1.40 0.81-2.42 0.23 58 0.03 (22)
  Kastrup et al, 2018 7 286 646 1.32 0.72-2.42 0.36 61 0.02 (23)
  Wang et al, 2020 7 356 717 1.31 0.80-2.13 0.29 61 0.02 (24)
  Xue et al, 2022 7 288 404 1.43 0.84-2.43 0.19 50 0.06 (25)
Bleeding None 7 39 21 3.13 1.65-5.95 <0.05 14 0.33  
Mortality None 6 30 51 1.37 0.55-3.41 0.50 45 0.10 (18,19,21-25)
  Urra et al, 2014 5 26 49 1.19 0.40-3.52 0.75 53 0.07 (18)
  Haussen et al, 2016 5 30 48 1.56 0.60-4.05 0.36 50 0.09 (19)
  Sarraj et al, 2018 5 19 50 1.07 0.46-2.48 0.87 33 0.20 (20)
  Nagel et al, 2018 5 27 31 1.94 1.02-3.69 0.04 2 0.40 (21)
  Wang et al, 2020 5 29 50 1.41 0.50-3.97 0.51 56 0.06 (22)
  Xue et al, 2022 5 19 27 1.27 0.34-4.75 0.73 53 0.08 (23)
Morbidity None 6 89 110 1.02 0.64-1.63 0.94 39 0.14 (18,19,21-24)
  Urra et al, 2014 5 75 96 0.95 0.55-1.64 0.85 45 0.12 (18)
  Haussen et al, 2016 5 88 105 1.07 0.65-1.75 0.80 47 0.11 (19)
  Sarraj et al, 2018 5 70 88 1.07 0.56-2.01 0.84 51 0.08 (22)
  Kastrup et al, 2018 5 81 74 1.16 0.70-1.94 0.56 35 0.19 (23)
  Nagel et al, 2018 5 54 82 1.10 0.58-1.09 0.78 50 0.09 (21)
  Wang et al, 2020 5 77 105 0.87 0.61-1.24 0.45 0 0.57 (24)